迪瑞醫療(300396.SZ):小而密低密度脂蛋白膽固醇測定試劑盒(過氧化物酶法)獲醫療器械註冊證
格隆匯 6 月 18日丨迪瑞醫療(300396.SZ)公佈,公司之控股子公司寧波瑞源生物科技有限公司(“寧波瑞源”)於近日取得由浙江省藥品監督管理局頒發的1項《醫療器械註冊證》,產品名稱為小而密低密度脂蛋白膽固醇測定試劑盒(過氧化物酶法)。
新取得試劑盒屬於生化分析產品,生化診斷是最早實現自動化的檢測手段,也是目前最常用的體外診斷方法之一。我國的體外診斷產業經過三十多年來的發展,已經形成了一定的規模並且與臨牀的需求基本相適應。目前,醫療衞生機構是消費生化試劑產品的主力軍。
上述《醫療器械註冊證》的取得,豐富了寧波瑞源的產品種類,將進一步增強公司控股子公司綜合競爭力,有利於進一步提高其市場拓展能力,對寧波瑞源未來的經營將產生積極影響。上述產品實際銷售情況取決於未來市場推廣效果,目前尚無法預測其對公司控股子公司未來業績的影響,敬請投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.